Vnitr Lek 2021, 67(1):e32-e42 | DOI: 10.36290/vnl.2021.015

Fever of unknown origin

Vyacheslav Grebenyuk1,2, Olga Kryštůfková3, Monika Gregová3, Magdalena Sokalská‑Jurkiewicz3, Renata Steinbauerová4, Marie Sukovská4, Lubica Gahérová5, Ivana Zubatá5, Jana Gregorová6, Lucia Kaliská7, Hana Roháčová2, Milan Trojánek1,2,8
1 Klinika infekčních nemocí, 2. lékařská fakulta, Univerzita Karlova, Praha
2 Klinika infekčních, parazitárních a tropických nemocí, Fakultní nemocnice Bulovka, Praha
3 Revmatologický ústav, Praha
4 Oddělení klinické hematologie, Fakultní nemocnice Bulovka, Praha
5 Interní hematologická klinika, 3. lékařská fakulta a Fakultní nemocnice Královské Vinohrady, Praha
6 Oddělení klinické farmacie, Praha
7 Oddělení nukleární medicíny, Proton Therapy Center Czech, Praha
8 Katedra infekčního lékařství, IPVZ, Praha

Fever of unknown origin is a rare clinical syndrome, that represents a significant diagnostic challenge. There have been described more than 200 potential diseases, that can manifest as a fever of unknown origin. These are classically divided into following categories: infections, non-infectious inflammatory diseases, malignancies, and other miscellaneous disorders. Each of the disease type is associated with rather characteristic symptoms, clinical signs and laboratory findings, which are individually non-specific, but may provide helpful clues for a further focused diagnostic work-up. The clinician's task is to be able to identify these hallmark clinical features and to correctly interpret their significance and limitations in the appropriate differential diagnostic context. The aim of this review is to provide up-to-date clinical research evidence and to propose a concise clue-oriented diagnostic approach.

Keywords: diagnostic imaging, differential diagnosis, fever, granulomatous diseases, infections, inflammation, medical history taking, neoplasms, physical examination, rheumatic diseases.

Published: March 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grebenyuk V, Kryštůfková O, Gregová M, Sokalská‑Jurkiewicz M, Steinbauerová R, Sukovská M, et al.. Fever of unknown origin. Vnitr Lek. 2021;67(1):e32-42. doi: 10.36290/vnl.2021.015.
Download citation

References

  1. Vanderschueren S, Knockaert D, Adriaenssens T, et al. From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 2003; 163(9): 1033-1041. Go to original source... Go to PubMed...
  2. Arnow PM, Flaherty JP. Fever of unknown origin. Lancet 1997; 350(9077): 575-580. Go to original source... Go to PubMed...
  3. Bleeker‑Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) 2007; 86(1): 26-38. Go to original source... Go to PubMed...
  4. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961; 40: 1-0. Go to original source... Go to PubMed...
  5. Durack DT, Street AC. Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis 1991; 11: 35-51. Go to PubMed...
  6. Knockaert DC, Vanneste LJ, Vanneste SB, et al. Fever of Unknown Origin in the 1980 s: An Update of the Diagnostic Spectrum. Arch Intern Med 1992; 152(1): 51-55. Go to original source...
  7. Hayakawa K, Ramasamy B, Chandrasekar PH. Fever of unknown origin: an evidence‑based review. Am J Med Sci 2012; 344(4): 307-316. Go to original source... Go to PubMed...
  8. de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine (Baltimore) 1997; 76(6): 392-400. Go to original source... Go to PubMed...
  9. Mourad O, Palda V, Detsky AS. A comprehensive evidence‑based approach to fever of unknown origin. Arch Intern Med 2003; 163(5): 545-551. Go to original source... Go to PubMed...
  10. Cunha BA, Lortholary O, Cunha CB. Fever of unknown origin: a clinical approach. Am J Med 2015; 128(10): 1138. e1-e15. Go to original source... Go to PubMed...
  11. Bleeker‑Rovers CP, van der Meer JWM. Fever of unknown origin. In: Kasper DL, Fauci AS, Longo DL, Hauser SL, Jameson JL, Loscalzo J (eds). Harrison's Principles of Internal Medicine. 19th ed. McGraw‑Hill: New York 2016: 135-142.
  12. Hersch EC, Oh RC. Prolonged febrile illness and fever of unknown origin in adults. Am Fam Physician 2014; 90(2): 91-96. Go to PubMed...
  13. Kouijzer IJE, Mulders‑Manders CM, Bleeker‑Rovers CP, et al. Fever of Unknown Origin: the Value of FDG‑PET/CT. Semin Nucl Med 2018; 48(2): 100-107. Go to original source... Go to PubMed...
  14. Mackowiak PA, Durack DT. Fever of unknown origin. In: Bennett JE, Dolin R, Blaser MJ, Parta M (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Elsevier Saunders: Philadelphia 2015: 721-729. Go to original source...
  15. Bottieau E, Clerinx J, Van den Enden E, et al. Fever after a stay in the tropics: diagnostic predictors of the leading tropical conditions. Medicine (Baltimore) 2007; 86(1): 18-25. Go to original source... Go to PubMed...
  16. Zenone T. Fever of unknown origin in rheumatic diseases. Infect Dis Clin North Am 2007; 21(4): 1115-1135. Go to original source... Go to PubMed...
  17. Gerfaud‑Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult‑onset Still's disease. Autoimmun Rev 2014; 13(7): 708-722. Go to original source... Go to PubMed...
  18. Foggo V, Cavenagh J. Malignant causes of fever of unknown origin. Clin Med (Lond) 2015; 15(3): 292-294. Go to original source... Go to PubMed...
  19. Chang JC, Gross HM. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. Am J Med 1984; 76: 597-603. Go to original source... Go to PubMed...
  20. Roush MK, Nelson KM. Understanding drug‑induced febrile reactions. Am Pharm 1993; 33(10): 39-42. Go to original source... Go to PubMed...
  21. Mackowiak PA. Drug fever: mechanisms, maxims and misconceptions. Am J Med Sci. 1987; 294(4): 275-286. Go to original source... Go to PubMed...
  22. Ochi H, Wada K, Okada H, et al. The persistence of drug‑induced fever by teicoplanin--a case report. Int J Clin Pharmacol Ther. 2011; 49(5): 339-343. Go to original source... Go to PubMed...
  23. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331(19): 1272-1285. Go to original source... Go to PubMed...
  24. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013; 68(5): 693.e1-e14. Go to original source... Go to PubMed...
  25. Cunha BA. Fever of unknown origin: focused diagnostic approach based on clinical clues from the history, physical examination, and laboratory tests. Infect Dis Clin North Am 2007; 21(4): 1137-1187. Go to original source... Go to PubMed...
  26. Kovačevičová M, Švestková S. Retikulární exantémy - patofyziologie, etiopatogeneze, klasifikace. Čes‑slov Derm 2012; 87(6): 211-219.
  27. Fogo A, du Vivier A. The cutaneous manifestations of haematological malignancy. Clin Med (Lond) 2009; 9(4): 366-370. Go to original source... Go to PubMed...
  28. Shmerling RH. Evaluation of the adult with polyarticular pain. UpToDate 2020. [cit. 2020-06-25]. Dostupné z www: .
  29. Gaddey HL, Riegel AM. Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis. Am Fam Physician 2016; 94(11): 896-903. Go to PubMed...
  30. Bona R. Evaluation of splenomegaly and other splenic disorders in adults. UpToDate 2020. [cit. 2020-06-25]. Dostupné z www: .
  31. Curry MP, Bonder A. Overwiew of the evaluation of hepatomegaly in adults. UpToDate. 2020 [cited 2020 Jun 25]. Dostupné z www: .
  32. Loughrey PB, Armstrong D, Lockhart CJ. Classical eye signs in bacterial endocarditis. QJM 2015; 108(11): 909-910. Go to original source... Go to PubMed...
  33. Ruddy SM, Bergstrom R, Tivakaran VS. Roth Spots. StatPearls 2020. [cit. 2020-06-25]. Dostupné z www: .
  34. Shane E. Diagnostic approach to hypercalcemia. UpToDate 2020. [cit. 2020-07-12]. Dostupné z www: < https://www.uptodate.com/contents/diagnostic‑approach‑to‑hypercalcemia>.
  35. Bray C, Bell LN, Liang H, et al. Erythrocyte Sedimentation Rate and C‑reactive Protein Measurements and Their Relevance in Clinical Medicine. WMJ 2016; 115(6): 317-321.
  36. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C‑reactive protein levels as markers of bacterial infection: a systematic review and meta‑analysis. Clin Infect Dis 2004; 39(2): 206-217. Go to original source... Go to PubMed...
  37. Maruna P. Proteiny akutní fáze. 1. vydání. Maxdorf: Praha 2004.
  38. Erez A, Shental O, Tchebiner JZ, et al. Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. Isr Med Assoc J 2014; 16(7): 439-443. Go to PubMed...
  39. Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin Med J (Engl) 2016; 129(4): 448-455. Go to original source... Go to PubMed...
  40. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol 2010; 125(Suppl 2): S238-S247. Go to original source... Go to PubMed...
  41. Dasgupta A, Wahed A. Protein Electrophoresis and Immunofixation. In Dasgupta A, Wahed A (authors). Clinical chemistry, immunology and laboratory quality control: A comprehensive review for board preparation, certification and clinical practice. 1st ed. Elsevier: Amsterdam 2014: 391-405. Go to original source...
  42. Casulo C, Maragulia J, Zelenetz AD. Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections. Clin Lymphoma Myeloma Leuk 2013; 13(2): 106-111. Go to original source... Go to PubMed...
  43. De Angelis F, Tosti ME, Capria S, et al. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non‑Hodgkin lymphomas: A retrospective cohort study. Leuk Res 2015; 39(12): 1382-1388. Go to original source... Go to PubMed...
  44. Guyomard S, Salles G, Coudurier M et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. Br J Haematol 2003; 123(1): 90-99. Go to original source... Go to PubMed...
  45. Coburn B, Morris AM, Tomlinson G, et al. Does this adult patient with suspected bacteremia require blood cultures? JAMA 2012; 308(5): 502-511. Go to original source... Go to PubMed...
  46. Werner M, Andersson R, Olaison L, et al. A clinical study of culture‑negative endocarditis. Medicine (Baltimore) 2003; 82(4): 263-273. Go to original source... Go to PubMed...
  47. Dibble EH, Yoo DC, Noto RB. Role of PET/CT in Workup of Fever without a Source. Radiographics 2016; 36(4): 1166-1177. Go to original source... Go to PubMed...
  48. Vilacosta I, Olmos C, de Agustín A, et al. The diagnostic ability of echocardiography for infective endocarditis and its associated complications. Expert Rev Cardiovasc Ther 2015; 13(11): 1225-1236. Go to original source... Go to PubMed...
  49. Censullo A, Vijayan T. Using Nuclear Medicine Imaging Wisely in Diagnosing Infectious Diseases. Open Forum Infect Dis 2017; 4(1): ofx011. Dostupné z DOI: . Go to original source... Go to PubMed...
  50. Hung BT, Wang PW, Su YJ, et al. The efficacy of 18 F‑FDG PET/CT and 67Ga SPECT/CT in diagnosing fever of unknown origin. Int J Infect Dis 2017; 62: 10-17. Go to original source... Go to PubMed...
  51. Seshadri N, Sonoda LI, Lever AM, et al. Superiority of 18 F‑FDG PET compared to 111In‑labelled leucocyte scintigraphy in the evaluation of fever of unknown origin. J Infect 2012; 65(1): 71-79. Go to original source... Go to PubMed...
  52. Roth AR, Basello GM. Approach to the adult patient with fever of unknown origin. Am Fam Physician 2003; 68(11): 2223-2228. Go to PubMed...
  53. Tan Y, Liu X, Shi X. Clinical features and outcomes of patients with fever of unknown origin: a retrospective study. BMC Infect Dis 2019; 19(1): 198. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.